255: Sarepta's pivotal moment, biotech's big week, & the future of Covid boosters
Our colleague Helen Branswell joins us to explain the latest news on Covid-19 boosters and the implications of a Marburg outbreak in Equatorial Guinea. Then we dive into the long history of a gene the...
20 Huhti 202339min
254: The legal battle over abortion, an FDA 'bully pulpit' and Moderna's future
Jeremy Levin, CEO of Ovid Therapeutics, joins us to discuss a judge’s decision to overturn the FDA approval of an abortion pill and why he believes it’s the biggest threat to the biopharma industry in...
13 Huhti 202340min
253: Illumina’s boardroom intrigue, the next big Alzheimer’s readout, & J&J’s creative lawyers
Our colleague Matthew Herper joins us for a deep dive into Illumina, explaining how the biggest company in genome sequencing lost the faith of shareholders and painted itself into a corner. We’ll also...
6 Huhti 202336min
252: Biotech's monkey shortage, the broken generics market, & conference cancel culture
We explain how biotech is affected by a bizarre situation involving smuggled monkeys, international intrigue, and a criminal investigation. We also discuss what leads to generic drug shortages, whethe...
30 Maalis 202336min
251: Bancel v. Bernie, Sarepta's FDA runaround, & Regeneron's ever-growing blockbuster
We discuss the theatrical merits and actual implications of Moderna CEO Stéphane Bancel's appearance before a committee led by Sen. Bernie Sanders. We also talk about the latest news in the life scien...
23 Maalis 202334min
250: SVB's long biotech shadow, pushy AI algorithms, & Icahn v. Illumina
STAT reporter Bob Herman joins us to explain how treatment algorithms powered by artificial intelligence are being used more frequently by Medicare Advantage plans to deny claims, even when continued ...
16 Maalis 202335min
249: Robert Califf on how drugs get approved, plus the nascent revolution in obesity
FDA Commissioner Robert Califf joins to discuss his first year on the job, the future of drug approvals, and how Duke basketball will do without Coach K. Then STAT’s Elaine Chen explains how powerful ...
9 Maalis 202338min
248: The next CRISPR fight, cheaper insulin, & an FDA shuffle
Our colleague Allison DeAngelis joins us to explain how the latest CRISPR breakthrough is shaping up to be a free-for-all among a multitude of companies and labs, including some of the biggest names i...
2 Maalis 202328min
